About Golgin subfamily A member 6B
Golgin subfamily A member 6B (GOLGA6B) is a protein
from Homo sapiens identified by UniProt accession
A6NDN3, 693 residues long.
MolForge cross-references it against 0 known binders and
5 disease associations.
Target properties
| Protein name | Golgin subfamily A member 6B |
| UniProt accession | A6NDN3 |
| Gene | GOLGA6B |
| Organism | Homo sapiens |
| Length | 693 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (5)
Diseases linked to this target (Open Targets).
- body height · score 0.03
- body mass index · score 0.02
- chronic hepatitis B virus infection · score 0.01
- cancer · score 0.01
- Prader-Willi syndrome · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NDN3-F1 | alphafold | PREDICTED | 72.40 | — |
Amino-acid sequence (693 residues)
MWPQPYLPPH PMMLEESRQN KLAAAKKKLK EYQQRKSPGI PAGAKTKKKK TDSSPETTTS GGGHSPGDSQ YQELAVALES SSVTISQLNE NIESLKQQKK QVEHQLEEAK KTNNEIHKAQ MERLETINIL TLEKADLKTT LYHTKRAARH FEEESKDLAG RLQYSLQRIQ ELERALCAVS TQQQEEDRSS SCREAVLHRR LQQTIKERAL LNAHVTQVTE SLKQVQLERD EYAKHIKGER ARWQERMWKM SVEARTLKEE KKRDIHRIQE LERSLSELKN QMAKPPSLAP PAVTSVVEQL QDEAKHLRQE VEGLEGKLQS QVENNQALSL LSKEQKQRLQ EQEEMLREQE VQRVREQERL CEQNERLREQ QKTLQEQGER LRKQEQRLRK QEERLRKEEE RLQKQEKRLW DQEERLWKKE ERLQKQEERL ALSQNHKLDK QLAEPQCSFE DLNNEKKSAL QLEQQVKELQ EKLDEEHLEA ASQQNQQLET QLSLVALPGE GDGGQHLDSE EEEAPRPTPN IPEDLESREA TSSFMDLPKE KADGTEQVER RELGFVQPSG VTDGMRESFT VYESQGAVPN TRHQEMEDVI RLAQKEEEMK VKLLELQELV LPLVGNHEGH GKFLIAAQNP ADEPTPGAPA PQELGAAGEQ DDFYEVSLDN NVEPAPGAAR EGSPHDNPTV QQIVQLSPVM QDT
Explore Golgin subfamily A member 6B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets